Copeland Capital Management LLC Acquires 53,138 Shares of Iradimed Corporation (NASDAQ:IRMD)

Copeland Capital Management LLC lifted its stake in Iradimed Corporation (NASDAQ:IRMD - Free Report) by 12.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 475,563 shares of the medical equipment provider's stock after purchasing an additional 53,138 shares during the quarter. Copeland Capital Management LLC owned 3.75% of Iradimed worth $26,156,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its stake in shares of Iradimed by 189.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 66,632 shares of the medical equipment provider's stock worth $3,351,000 after buying an additional 43,635 shares in the last quarter. Eagle Asset Management Inc. purchased a new position in shares of Iradimed in the third quarter worth $1,239,000. Allspring Global Investments Holdings LLC boosted its position in shares of Iradimed by 14.4% during the third quarter. Allspring Global Investments Holdings LLC now owns 20,122 shares of the medical equipment provider's stock valued at $1,012,000 after buying an additional 2,538 shares during the last quarter. Barclays PLC increased its holdings in Iradimed by 113.9% in the 3rd quarter. Barclays PLC now owns 23,774 shares of the medical equipment provider's stock worth $1,196,000 after buying an additional 12,657 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in Iradimed by 70.2% in the third quarter. JPMorgan Chase & Co. now owns 29,226 shares of the medical equipment provider's stock worth $1,470,000 after purchasing an additional 12,051 shares during the last quarter. 92.34% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Iradimed

In other news, CFO John Glenn sold 2,500 shares of the business's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $54.18, for a total value of $135,450.00. Following the transaction, the chief financial officer now owns 4,383 shares of the company's stock, valued at approximately $237,470.94. The trade was a 36.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 37.10% of the company's stock.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded Iradimed from a "strong-buy" rating to a "buy" rating in a research note on Wednesday.

Iradimed Price Performance

Shares of NASDAQ:IRMD traded up $1.75 during midday trading on Wednesday, hitting $62.98. The company had a trading volume of 43,113 shares, compared to its average volume of 37,539. Iradimed Corporation has a 12-month low of $40.18 and a 12-month high of $63.29. The company has a fifty day moving average of $56.30 and a two-hundred day moving average of $51.47. The company has a market cap of $797.99 million, a price-to-earnings ratio of 43.15 and a beta of 0.82.

Iradimed Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.